CN1452495A - 抗微生物病原体的疫苗 - Google Patents

抗微生物病原体的疫苗 Download PDF

Info

Publication number
CN1452495A
CN1452495A CN01815133A CN01815133A CN1452495A CN 1452495 A CN1452495 A CN 1452495A CN 01815133 A CN01815133 A CN 01815133A CN 01815133 A CN01815133 A CN 01815133A CN 1452495 A CN1452495 A CN 1452495A
Authority
CN
China
Prior art keywords
vaccine
gene
microbial pathogens
inactivation
aforementioned arbitrary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01815133A
Other languages
English (en)
Chinese (zh)
Inventor
卡米洛·安东尼·利奥·塞尔温·科拉索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Publication of CN1452495A publication Critical patent/CN1452495A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN01815133A 2000-09-04 2001-09-04 抗微生物病原体的疫苗 Pending CN1452495A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021757.0A GB0021757D0 (en) 2000-09-04 2000-09-04 Vaccine against microbial pathogens
GB0021757.0 2000-09-04

Publications (1)

Publication Number Publication Date
CN1452495A true CN1452495A (zh) 2003-10-29

Family

ID=9898866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01815133A Pending CN1452495A (zh) 2000-09-04 2001-09-04 抗微生物病原体的疫苗

Country Status (15)

Country Link
US (1) US20050232946A1 (https=)
EP (1) EP1315518B1 (https=)
JP (1) JP2004508339A (https=)
CN (1) CN1452495A (https=)
AT (1) ATE450270T1 (https=)
AU (1) AU2001284261A1 (https=)
CA (1) CA2421229A1 (https=)
DE (1) DE60140681D1 (https=)
DK (1) DK1315518T3 (https=)
ES (1) ES2337653T3 (https=)
GB (1) GB0021757D0 (https=)
IL (1) IL154727A0 (https=)
PT (1) PT1315518E (https=)
WO (1) WO2002020045A2 (https=)
ZA (1) ZA200301759B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781487A (zh) * 2011-04-20 2014-05-07 米科生物公司 用于增强免疫应答的组合物和方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928264B2 (en) * 2004-09-21 2011-04-19 Astellas Pharma Inc. Aminoalcohol derivatives
CN101522213A (zh) 2006-09-01 2009-09-02 Csl有限公司 引起或诱导免疫应答的方法
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
NZ583377A (en) 2007-10-12 2013-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3020226B2 (ja) * 1986-08-18 2000-03-15 ブリティッシュ・テクノロジー・グループ・リミテッド ワクチン
US5776724A (en) * 1988-10-24 1998-07-07 Yale University Chaperonin-mediated protein folding
JPH03204820A (ja) * 1989-10-12 1991-09-06 Nippon Saibai Suisan Kk エビ類の細菌性疾病予防ワクチン及びその製造法
WO1995014093A1 (en) * 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH0748398A (ja) * 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US6872542B1 (en) * 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US7022328B1 (en) * 1995-11-30 2006-04-04 Australian Pork Limited Therapeutic and diagnostic compositions
IN183280B (https=) * 1996-09-20 1999-10-30 Univ New Mexico
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6500434B1 (en) * 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
NZ509127A (en) * 1998-06-19 2004-01-30 Merieux Oravax Use of LT (E. coli) and CT (cholera toxin) for inducing immune responses against helicobacter infection
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
CA2363146A1 (en) * 1999-02-22 2000-08-31 Solomon Langermann Caulobacter lps immunoadjuvant
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
WO2001078772A1 (en) * 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
US6932985B2 (en) * 2000-10-10 2005-08-23 Auburn University Azide method and composition for controlling deleterious organisms
WO2002059156A2 (en) * 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US8088569B2 (en) * 2002-03-01 2012-01-03 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
EP1539223A2 (en) * 2002-05-02 2005-06-15 University of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781487A (zh) * 2011-04-20 2014-05-07 米科生物公司 用于增强免疫应答的组合物和方法

Also Published As

Publication number Publication date
AU2001284261A1 (en) 2002-03-22
ATE450270T1 (de) 2009-12-15
CA2421229A1 (en) 2002-03-14
IL154727A0 (en) 2003-10-31
JP2004508339A (ja) 2004-03-18
GB0021757D0 (en) 2000-10-18
ES2337653T3 (es) 2010-04-28
WO2002020045A3 (en) 2002-10-31
US20050232946A1 (en) 2005-10-20
DE60140681D1 (de) 2010-01-14
EP1315518A2 (en) 2003-06-04
PT1315518E (pt) 2010-03-05
DK1315518T3 (da) 2010-04-19
WO2002020045A2 (en) 2002-03-14
ZA200301759B (en) 2004-06-22
EP1315518B1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
US7635479B2 (en) Composition and methods for enhancing immunogenecity of antigens
Gupta et al. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis
US20020025323A1 (en) Compositions and methods for enhancing immunogenicity of antigens
Chambers et al. Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83
Jawale et al. Evaluation of immunogenicity and protective efficacy of adjuvanted Salmonella Typhimurium ghost vaccine against salmonellosis in chickens
Singh Salmonella vaccines for animals and birds and their future perspective
CN1452495A (zh) 抗微生物病原体的疫苗
US10669563B2 (en) Method for the production of protein complexes and vaccine compositions comprising the same
US20050175635A1 (en) Method and composition
CN100523192C (zh) 来自感染因子的疫苗
CN1251761C (zh) 包含细胞因子诱导的热休克蛋白(hsp)的疫苗
WANG et al. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin‐2 against Mycobacterium tuberculosis in BALB/c mice
CN1182871C (zh) 抗胞内病原体的疫苗
AU2005204321B2 (en) Vaccines from Infectious Agents
Kennedy The view on vaccination.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication